Aprea Therapeutics Inc (APRE) - Total Assets
Based on the latest financial reports, Aprea Therapeutics Inc (APRE) holds total assets worth $14.32 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See APRE total equity for net asset value and shareholders' equity analysis.
Aprea Therapeutics Inc - Total Assets Trend (2007–2024)
This chart illustrates how Aprea Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Aprea Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Aprea Therapeutics Inc's total assets of $14.32 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Aprea Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Aprea Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aprea Therapeutics Inc's current assets represent 98.3% of total assets in 2024, an increase from 3.6% in 2007.
- Cash Position: Cash and equivalents constituted 95.3% of total assets in 2024, up from 1.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aprea Therapeutics Inc Competitors by Total Assets
Key competitors of Aprea Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Aprea Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.20 | 7.28 | 6.03 |
| Quick Ratio | 5.20 | 7.28 | 6.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $11.26 Million | $22.85 Million | $77.09 Million |
Aprea Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Aprea Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.87 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 5.9% |
| Total Assets | $23.98 Million |
| Market Capitalization | $9.37 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aprea Therapeutics Inc's assets below their book value (0.39x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Aprea Therapeutics Inc's assets grew by 5.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Aprea Therapeutics Inc (2007–2024)
The table below shows the annual total assets of Aprea Therapeutics Inc from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $23.98 Million | +5.87% |
| 2023-12-31 | $22.65 Million | -24.89% |
| 2022-12-31 | $30.16 Million | -46.93% |
| 2021-12-31 | $56.82 Million | -38.77% |
| 2020-12-31 | $92.81 Million | -30.54% |
| 2019-12-31 | $133.61 Million | +102.37% |
| 2018-12-31 | $66.02 Million | +166.63% |
| 2017-12-31 | $24.76 Million | +7749.25% |
| 2007-12-31 | $315.47K | -- |
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tum… Read more